Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug1786 | LY3819253 Wiki | 0.71 |
drug3557 | Usual Care Wiki | 0.18 |
drug808 | Colchicine Wiki | 0.15 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
D007239 | Infection NIH | 0.03 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There are 3 clinical trials
The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19, via an injection into a vein. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone.
Description: Change from Baseline to Day 11 in SARS-CoV-2 Viral Load
Measure: Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Time: Baseline, Day 11Description: Percentage of Participants Who Experience COVID-Related Hospitalization or Death
Measure: Percentage of Participants Who Experience COVID-Related Hospitalization or Death Time: Baseline through Day 29Description: Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold
Measure: Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold Time: Day 7Description: Change from Baseline to Day 11 in SARS-CoV-2 Viral Load Among Participants Enrolled with Recent Symptoms Prior to Randomization
Measure: Change from Baseline to Day 11 in SARS-CoV-2 Viral Load Among Participants Enrolled with Recent Symptoms Prior to Randomization Time: Baseline, Day 11Description: Percentage of Participants Demonstrating Symptom Resolution
Measure: Percentage of Participants Demonstrating Symptom Resolution Time: Day 11Description: Percentage of Participants Demonstrating Symptom Improvement
Measure: Percentage of Participants Demonstrating Symptom Improvement Time: Day 11Description: PK: Mean Concentration of LY3819253 and LY3819253 in the Presence of LY3832479
Measure: Pharmacokinetics (PK): Mean Concentration of LY3819253 and LY3819253 in the Presence of LY3832479 Time: Day 29Description: PK: Mean Concentration of LY3832479 in the Presence of LY3819253
Measure: PK: Mean Concentration of LY3832479 in the Presence of LY3819253 Time: Day 29Description: Percentage of Participants Who Experience COVID-Related Hospitalization, COVID-Related ER Visit, or Death
Measure: Percentage of Participants Who Experience COVID-Related Hospitalization, COVID-Related Emergency Room (ER) Visit, or Death Time: Baseline through Day 85Description: Change from Baseline to Day 7 in SARS-CoV-2 Viral Load
Measure: Change from Baseline to Day 7 in SARS-CoV-2 Viral Load Time: Baseline, Day 7Description: Percentage of Participants Enrolled with Recent Symptoms Prior to Randomization Who Experience COVID-Related Hospitalization or Death
Measure: Percentage of Participants Enrolled with Recent Symptoms Prior to Randomization Who Experience COVID-Related Hospitalization or Death Time: Baseline through Day 29The purpose of this study is to evaluate whether LY3819253 given alone and with LY3832479 prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease - 2019 (COVID-19). Facility staff and residents in contracted skilled nursing and assisted living facility networks with a high risk of SARS-CoV-2 exposure will receive LY3819253, LY3819253 and LY3832479, or placebo via an injection into a vein. Samples will be taken from the nose. Blood samples will be drawn. Participation could last up to 25 weeks and may include up to 19 visits.
Description: Percentage of Participants with COVID-19 within 21 Days of Detection
Measure: Percentage of Participants with COVID-19 within 21 Days of Detection Time: Baseline through Week 8Description: Percentage of Participants with Moderate or Worse Severity COVID-19 within 21 Days of Detection
Measure: Percentage of Participants with Moderate or Worse Severity COVID-19 within 21 Days of Detection Time: Baseline through Week 8Description: Percentage of Participants with SARS-CoV-2
Measure: Percentage of Participants with SARS-CoV-2 Time: Baseline through Week 4Description: Percentage of Participants Who are Hospitalized or Have Died due to COVID-19
Measure: Percentage of Participants Who are Hospitalized or Have Died due to COVID-19 Time: Week 8Description: Percentage of Participants who Experience COVID-19-Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death
Measure: Percentage of Participants who Experience COVID-19-Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death Time: Week 8Description: Percentage of Participants Who Die Due to COVID-19
Measure: Percentage of Participants Who Die Due to COVID-19 Time: Week 8Description: PK: Mean Concentration of LY3819253 Administered Alone
Measure: Pharmacokinetics (PK): Mean Concentration of LY3819253 Administered Alone Time: Day 29Description: PK: Mean Concentration of LY3819253 in the Presence of LY3832479
Measure: PK: Mean Concentration of LY3819253 in the Presence of LY3832479 Time: Day 29Description: PK: Mean Concentration of LY3832479 in the Presence of LY3819253
Measure: PK: Mean Concentration of LY3832479 in the Presence of LY3819253 Time: Day 29The purpose of this study is to measure how well LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 weeks and includes at least 1 visit to the study site, with the remainder of assessments performed in the home, local clinic, or by phone.
Description: Percentage of Participants with SARS-CoV-2 Viral Load Greater than 5.27
Measure: Percentage of Participants with SARS-CoV-2 Viral Load Greater than 5.27 Time: Day 7Description: Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death
Measure: Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death Time: Baseline through Day 29Description: Change from Baseline to Day 7 in SARS-CoV-2 Viral Load
Measure: Change from Baseline to Day 7 in SARS-CoV-2 Viral Load Time: Baseline, Day 7Description: Percentage of Participants Demonstrating Symptom Resolution
Measure: Percentage of Participants Demonstrating Symptom Resolution Time: Day 7Description: Percentage of Participants Demonstrating Symptom Improvement
Measure: Percentage of Participants Demonstrating Symptom Improvement Time: Day 7Description: Percentage of Participants Who Experience COVID-Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death
Measure: Percentage of Participants Who Experience COVID-Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death Time: Baseline through Day 22Description: Pharmacokinetics (PK): Mean Concentration of LY3819253 and LY3832479
Measure: Pharmacokinetics (PK): Mean Concentration of LY3819253 and LY3832479 Time: Day 29Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports